2-bromo-1-(2-chloro-4-methoxyphenyl)propan-1-one | 188120-55-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-1-(2-chloro-4-methoxyphenyl)propan-1-one
• 英文别名: 2-bromo-1-(2-chloro-4-methoxyphenyl)-1-propanone；2-bromo-1-(2-chloro-4-methoxyphenyl)propane-1-one；2-Bromo-1-(2-chloro-4-methoxyphenyl)-propan-1-one
• CAS: 188120-55-0
• 化学式: C₁₀H₁₀BrClO₂
• 分子量: 277.545
• InChiKey: JDUMYIRHFTZPHA-UHFFFAOYSA-N

物化性质

• 沸点：
  322.1±27.0 °C(Predicted)
• 密度：
  1.484±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(2-chloro-4-methoxyphenyl)propan-1-one 在 三溴化硼 、 potassium carbonate 作用下， 以 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 90.0h， 生成 2,4-bis(2-chloro-4-hydroxyphenyl)-1-(4-hydroxyphenyl)-5-methyl-1H-imidazole
  参考文献：
  名称：

  Structure−Activity Relationship Study To Understand the Estrogen Receptor-Dependent Gene Activation of Aryl- and Alkyl-Substituted 1H-Imidazoles

  摘要：

  A series of C5-substituted 1,2,4-triaryl-1H-imidazoles was synthesized. Their gene-activating properties were determined on estrogen receptor alpha positive MCF-7 breast cancer cells, stably transfected with the plasmid ERE(wtc)luc (MCF-7-2a cells). The influence of 4-OH and 2-Cl substituents on the phenyl rings as well as the significance of a methyl, ethyl, or phenyl group at C5 on the estrogen receptor binding and the resulting gene activation in MCF-7-2a cells was studied. The alkyl and aryl groups at C5 of 1,2,4-tris(4-hydroxyphenyl)-1H-imidazole 1 increased the transactivation, while chlorine atoms on the phenyl rings diminished this effect. 5-Ethyl-1,2,4-tris(4-hydroxyphenyl)-1H-imidazole 9 was identified as the most active compound. Its excellent transcriptional activity did not only depend on the C5 ethyl group, but also on the three hydroxyl groups of the phenyl rings. Compounds (11-14) with a reduced number of hydroxyl groups displayed distinctly lower gene activation.

  DOI：

  10.1021/jm061106t
• 作为产物：
  描述：

  2-chloro-4-methoxypropiophenone 在 phenyltrimethylammonium tribromide 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 生成 2-bromo-1-(2-chloro-4-methoxyphenyl)propan-1-one
  参考文献：
  名称：

  BICYCLIC HETEROCYCLIC COMPOUND

  摘要：

  公式（I）表示的化合物，其盐，其N-氧化物，其溶剂合物或其前药：其中X，Y和W分别独立表示碳原子或氮原子；Z表示CH或氮原子；R1表示（1）可能被取代的C3-10支链烷基或（2）-(CH2)m-NR4R5；R2和R3分别独立表示（1）氢原子，（2）可能被卤原子取代的C1-4烷基，可能被保护的羟基，可能被保护的氨基，或可能被保护的羧基，（3）C2-4烯基，（4）C2-4炔基，（5）腈基，（6）COOR6，（7）CONR7R8，（8）COR101，（9）S（O）nR102，或（10）卤原子，其中R6表示氢原子或C1-4烷基，R7和R8分别独立表示氢原子或C1-4烷基，R101表示氢原子或C1-4烷基，R102表示C1-4烷基，n表示1或2；Ar表示可能被取代的芳香环，用作在预防和/或治疗神经精神疾病，外周器官疾病等方面具有CRF拮抗作用的药理活性成分。

  公开号：

  EP1961745A1

文献信息

• Organic compounds
  申请人：Bruce Ian

  公开号：US20100035874A1

  公开（公告）日：2010-02-11

  There are described pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF 1 ) receptor antagonists.

  描述了作为促肾上腺皮质激素释放因子（CRF1）受体拮抗剂有用的吡唑并[5.1-b]噁唑衍生物。
• Substituted 4-phenylaminothiazoles, their process of preparation and the
  申请人：Sanofi

  公开号：US05880135A1

  公开（公告）日：1999-03-09

  A compound, as well as its stereoisomers and addition salts, possssing antagonist activity with respect to corticotropin releasing hormone (CRF) has the formula: ##STR1## in which R.sub.1, and R.sub.21 which are identical or different, are independently selected from a halogen atom; a (C.sub.1 -C.sub.5)hydroxyalkyl radical; a (C.sub.1 -C.sub.5)alkyl; a (C.sub.7 -C.sub.10)aralkyl; a (C.sub.1 -C.sub.5)alkoxy; a trifluoromethyl; a nitro; a nitrile; an --SR group in which R is selected from hydrogen, a (C.sub.1 -C.sub.5)alkyl radical and a (C.sub.7 -C.sub.10)aralkyl radical; an --S--CO--R group in which R is selected from a (C.sub.1 -C.sub.5)alkyl radical and an aralkyl radical in which the aryl part is (C.sub.6 -C.sub.8) and the alkyl part is (C.sub.1 -C.sub.4); a --COOR' group in which R' is selected from hydrogen and a (C.sub.1 -C.sub.5)alkyl; a --CONR--R'R" group with R' and R" as defined above for R'; an --NR'R" group with R' and R" as defined above for R'; a --CONRaRb or --NRaRb group in which Ra and Rb constitute, with the nitrogen atom to which they are bonded, a 5- to 7-membered heterocycle; and an --NHCO--NR'R" group with R' and R" as defined above for R'; R.sub.3 represents hydrogen or is as defined above for R.sub.1 and R.sub.2 ; R.sub.4 is selected from a hydrogen atom; a (C.sub.1 -C.sub.5)alkyl; a halogen, a hydroxymethyl group; and a formyl group; R.sub.5 is selected from a (C.sub.1 -C.sub.5)alkyl; a (C.sub.3 -C.sub.7)cycloalkyl group; a cycloalkylalkyl group in which the cycloalkyl part is (C.sub.3 -C.sub.7) and the alkyl part is (C.sub.1 -C.sub.5); and alkenyl containing 5 to 6 carbon atoms; n represents zero or one; R.sub.6 is selected from a (C.sub.1 -C.sub.5)alkyl; an alkoxyalkyl in which the alkyl parts are (C.sub.1 -C.sub.5); a (C.sub.3 -C.sub.7)cycloalkyl; a cycloalkylalkyl group in which the cycloalkyl part is (C.sub.3 -C.sub.7) and the alkyl part is (C.sub.1 -C.sub.5); a cycloalkyloxyalkyl radical in which the cycloalkyl is (C.sub.3 -C.sub.7) and the alkyl part is (C.sub.1 -C.sub.4); a hydroxyalkyloxyalkyl radical in which the alkyls are (C.sub.2 -C.sub.10); and an alkoxyalkyloxyalkyl radical in which the alkyls are (C.sub.3 -C.sub.12); Z represents an optionally substituted bi- or tricyclic aromatic or heteroaromatic group.

  一种化合物及其立体异构体和加合盐，具有对促肾上腺皮质激素释放激素（CRF）的拮抗活性，其化学式为：##STR1##其中R.sub.1和R.sub.2，相同或不同，独立地选自卤素原子；（C.sub.1-C.sub.5）羟基烷基基团；（C.sub.1-C.sub.5）烷基；（C.sub.7-C.sub.10）芳基烷基；（C.sub.1-C.sub.5）烷氧基；三氟甲基；硝基；腈基；--SR基团，其中R选自氢、（C.sub.1-C.sub.5）烷基基团和（C.sub.7-C.sub.10）芳基烷基基团；--S--CO--R基团，其中R选自（C.sub.1-C.sub.5）烷基基团和芳基烷基基团，其中芳基部分为（C.sub.6-C.sub.8），烷基部分为（C.sub.1-C.sub.4）；--COOR'基团，其中R'选自氢和（C.sub.1-C.sub.5）烷基；--CONR--R'R"基团，其中R'和R"如上所定义；--NR'R"基团，其中R'和R"如上所定义；--CONRaRb或--NRaRb基团，其中Ra和Rb与它们连接的氮原子构成5-至7-成员杂环；--NHCO--NR'R"基团，其中R'和R"如上所定义；R.sub.3代表氢或如上所定义的R.sub.1和R.sub.2；R.sub.4选自氢原子；（C.sub.1-C.sub.5）烷基；卤素；羟甲基基团；和甲酰基；R.sub.5选自（C.sub.1-C.sub.5）烷基；（C.sub.3-C.sub.7）环烷基基团；环烷基烷基基团，其中环烷基部分为（C.sub.3-C.sub.7），烷基部分为（C.sub.1-C.sub.5）；和含有5至6个碳原子的烯基；n表示零或一；R.sub.6选自（C.sub.1-C.sub.5）烷基；烷氧基烷基，其中烷基部分为（C.sub.1-C.sub.5）；（C.sub.3-C.sub.7）环烷基；环烷基烷基基团，其中环烷基部分为（C.sub.3-C.sub.7），烷基部分为（C.sub.1-C.sub.5）；环烷氧基烷基基团，其中环烷基为（C.sub.3-C.sub.7），烷基部分为（C.sub.1-C.sub.4）；羟基烷氧基烷基基团，其中烷基为（C.sub.2-C.sub.10）；和烷氧基烷氧基烷基基团，其中烷基为（C.sub.3-C.sub.12）；Z代表可选择地取代的双环或三环芳香或杂芳基。
• [EN] AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS<br/>[FR] DERIVES D'AMINOTHIAZOLE ET LEUR UTILISATION COMME LIGANDS DES RECEPTEURS CRF
  申请人：SANOFI SYNTHELABO

  公开号：WO2001005776A1

  公开（公告）日：2001-01-25

  La présente invention concerne les composés de formule (I) dans laquelle R1, R2, R3, R4, R5, R6 et R7 sont tels que définis dans la revendication 1. Ces composés sont affins pour les récepteurs du CRF.

  本发明涉及具有式（I）的化合物，其中R1，R2，R3，R4，R5，R6和R7如权利要求1中所定义。这些化合物对CRF受体具有亲和力。
• Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them
  申请人：——

  公开号：US20020137740A1

  公开（公告）日：2002-09-26

  The subject of the invention is the compounds of formula: 1 in which R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in Claim 1. The compounds have a high affinity for the CRF receptors.

  本发明的主题是公式1中的化合物：其中R1，R2，R3，R4，R5和R6如权利要求书1所定义的那样。这些化合物具有高亲和力CRF受体。
• Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same
  申请人：Sanofi-Synthelabo

  公开号：US06344470B1

  公开（公告）日：2002-02-05

  The subject of the invention is the compounds of formula: in which R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. The compounds have a high affinity for CRF receptors.

  本发明的主题是化学式为：其中R1，R2，R3，R4，R5和R6如权利要求书1所定义的化合物。这些化合物对CRF受体具有高亲和力。